Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The company's lead product candidate, entinostat, is a selective HDAC inhibitor that has been evaluated in multiple clinical trials in combination with immune checkpoint inhibitors and targeted therapies. Syndax is also developing SNDX-5613, a highly selective and potent inhibitor of the Menin-MLL interaction, for the treatment of acute leukemias. The company is committed to improving the lives of cancer patients through the discovery and development of novel therapies.
Highest paying job titles at Syndax Pharmaceuticals include Accountant, Accounting Manager, and Clinical Research Scientist